阿戈美拉汀就是一垃圾产品,真不知道怎么通过FDA批准的
Eric.Liu 发表于 13-10-31 13:05
阿戈美拉汀没通过FDA的批准,只通过欧洲的批准。
诺华放弃阿戈美拉汀在美国的市场了。
Novartis drops future blockbuster agomelatine
25 October 2011
Eleanor Malone
Novartis has stopped development of agomelatine (AGO178) in major depressive disorder. The product had already been approved in the EU (where it is sold by Servier as Valdoxan) and US approval was expected to ensue in 2013, with peak sales of $2.6 billion for depression alone in the seven major markets.. |